Vimgreen Completes Phase 2 Trial Enrollment for VG081821AC in Parkinson's Disease

Vimgreen Pharmaceuticals, a science-driven company specializing in adenosine signaling modulation, has successfully completed the enrollment for its Phase 2 clinical trial of VG081821AC. This trial focuses on VG081821, a pioneering adenosine A2A receptor (A2AR) antagonist that also serves as an inverse A2AR agonist, aimed at treating patients with early-to-mid stage Parkinson's disease (PD). A total of 150 participants have been enlisted and allocated into three groups: a high-dose VG081821 group, a low-dose VG081821 group, and a placebo group, each comprising an equal number of participants.

The Phase 2 trial spans 12 weeks and is conducted across multiple centers. It is designed as a randomized, placebo-controlled, double-blind study to examine the safety and efficacy of VG081821 when used as a monotherapy for patients in the early-to-mid stages of PD. The primary goal is to measure the difference in the change from baseline in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III motor symptoms score between the VG081821 groups and the placebo group over the 12-week period.

Current treatments for PD primarily rely on dopamine replacement strategies, including L-Dopa, dopamine agonists, MAO-B inhibitors, and COMT inhibitors. These medications either boost dopamine levels or mimic its functions. While L-Dopa is effective in alleviating PD's motor symptoms, long-term use often leads to complications such as wearing-off, ON–OFF phenomena, and dyskinesia. Additionally, these treatments are purely symptomatic and do not slow PD progression.

VG081821 offers a different approach as an A2AR antagonist, functioning non-dopaminergically, which may help in avoiding, reducing, or delaying motor complications if used early in the treatment process. Uniquely, VG081821 acts as both a potent A2A antagonist and an inverse A2A receptor agonist. This dual action could provide additional therapeutic benefits and greater efficacy in addressing PD's motor dysfunctions. Moreover, VG081821 may offer not only symptomatic relief but also disease-modifying benefits, presenting a promising new treatment option for PD patients.

Sanxing Sun, President and CEO of Vimgreen, commented on the unique approach of VG081821, stating that unlike previous A2A antagonists used in conjunction with L-Dopa for advanced PD patients, VG081821 is intended to be used as a standalone treatment in early-to-mid stages of PD. It can later be combined with low doses of L-Dopa as the disease progresses, potentially minimizing L-Dopa's complications and extending the quality of life for PD patients.

The Phase 2 trial also aims to analyze A2AR gene expression levels in peripheral blood mononuclear cells (PBMCs) of the participants. A potential correlation between the drug's efficacy and A2AR expression levels could position VG081821 as a precision medicine for PD treatment.

The trial is scheduled for completion in November.

VG081821AC Overview:
VG081821AC, also known as VG081821, is a potent and selective A2AR antagonist developed by Vimgreen. A2A receptors, predominantly found in the basal ganglia and striatum, are crucial in regulating motor functions, making them a compelling non-dopaminergic target for PD treatment. VG081821's innovative dual action as an antagonist and inverse agonist promises enhanced treatment options and clinical benefits for PD patients.

About Vimgreen Pharmaceuticals:
Based in Hangzhou, China, Vimgreen Pharmaceuticals focuses on modulating adenosine signaling, a critical molecule involved in numerous physiological processes, including the nervous system, immune response, vascular function, and metabolism. Vimgreen's research has revealed therapeutic possibilities in treating various diseases by either enhancing or inhibiting adenosine signaling pathways. They have two compounds currently in clinical development: VG081821 for PD and VG290131, an A3 agonist for treating NASH.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!